Laila Gharzai, MD, discusses findings from the BRIGHTSTAR trial which evaluated brigatinib in TKI-naïve patients with ALK-rearranged metastatic non–small cell lung cancer.
Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC
Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.
Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.
IMM2510/AXN-2510 Combo Yields Preliminary Responses in Advanced NSCLC
The treatment combination elicited partial responses in 80% of patients with squamous NSCLC and 46% in nonsquamous NSCLC.
Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting
Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
DB-1310 Earns FDA Fast Track Designation in EGFR-Mutant Nonsquamous NSCLC
Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.
Osimertinib Combo Significantly Prolongs Survival in Advanced EGFR+ NSCLC
Investigators will present updated findings from the phase 3 FLAURA2 trial at a future medical meeting.